Sirion Biotech GmbH, a Munich, Germany-based specializes in viral vector platforms and provides sophisticated cell modeling, closed a financing round of undisclosed amount.
The company intends to use the new funds to further strengthen access to the Japan and USA markets and drive the evaluation of clinical programs for viral vectors and commercial projects for novel cell models.
Founded in 2006, the company is led by Dr. Christian Thirion, Chief Technology Officer, and Dieter Lingelbach,
Chief Operating Officer, Sirion Biotech designs viral vectors and creates custom cell models for compound development in the drug, cosmetics and food industries.
The company’s technologies have been validated in over 300 single projects with more than 100 academic and industrial partners.